The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension.

Gibbons CH, Schmidt P, Biaggioni I, Frazier-Mills C, Freeman R, Isaacson S, Karabin B, Kuritzky L, Lew M, Low P, Mehdirad A, Raj SR, Vernino S, Kaufmann H. · 2017

Read The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. by Gibbons CH, Schmidt P, Biaggioni I, Frazier-Mills C, Freeman R, Isaacson S, Karabin B, Kuritzky L, Lew M, Low P, Mehdirad A, Raj SR, Vernino S, Kaufmann H. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5533816.txt.

Introduction

Gibbons and a consensus panel present recommendations in the Journal of Neurology on neurogenic orthostatic hypotension. In this condition, blood pressure crashes on standing because autonomic nerves fail. It haunts Parkinson's disease, multiple system atrophy, and related disorders. Many patients also suffer high pressure while lying flat. Past studies used clashing definitions, so no shared guideline existed.

The panel sets out who to screen and how to confirm the diagnosis. It then lays out treatment steps, naming drugs like droxidopa and midodrine. Lying hypertension gets its own management advice. The statement aims at primary care doctors as much as specialists.

Catalog record

CREATORGibbons CH, Schmidt P, Biaggioni I, Frazier-Mills C, Freeman R, Isaacson S, Karabin B, Kuritzky L, Lew M, Low P, Mehdirad A, Raj SR, Vernino S, Kaufmann H.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE72 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5533816

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension By Christopher H Gibbons, Peter Schmidt, Italo Biaggioni, Camille Frazier-Mills, Roy Freeman, Stuart Isaacson, Beverly Karabin, Louis Kuritzky, Mark Lew, Phillip Low, Ali Mehdirad, Satish R Raj Published in: Journal of Neurology DOI: 10.1007/s00415-016-8375-x ABSTRACT Abstract Neurogenic orthostatic hypotension (nOH) is common in patients with neurodegenerative disorders such as Parkinson’s disease, multiple system atrophy, pure autonomic failure, dementia with Lewy bodies, and peripheral neuropathies including amyloid or diabetic neuropathy. Due to the frequency of nOH in the aging population, clinicians need to be well informed about its diagnosis and management. To date, studies of nOH have used different outcome measures and various methods of diagnosis, thereby preventing the generation of evidence-based guidelines to direct clinicians towards ‘best practices’ when treating patients with nOH and associated supine hypertension. To address these issues, the American Autonomic Society and the National Parkinson Foundation initiated a project to develop a statement of recommendations beginning with a consensus panel meeting in Boston on November 7, 2015, with continued communications and contributions to the recommendations through October of 2016. This paper summarizes the panel members’ discussions held during the initial meeting along with continued deliberations among the panel members and provides essential recommendations based upon best available evidence as well as expert opinion for the (1) screening, (2) diagnosis, (3) treatment of nOH, and (4) diagnosis and treatment of associated supine hypertension. Electronic supplementary material The online version of this article (doi:10.1007/s00415-016-8375-x) contains supplementary material, which is available to authorized users. Keywords: Neurogenic orthostatic hypotension, Supine hypertension, Autonomic dysfunction, Droxidopa, Midodrine, Fludrocortisone INTRODUCTION Neurogenic orthostatic hypotension (nOH) is a prevalent disorder [1, 2]. Clinicians from a variety of specialties need to be well informed about diagnosis and management of nOH as it carries a significant burden of morbidity and has also been associated with increased mortality [3–5]. Clinicians should, therefore, familiarize themselves with this condition and evolving management options, which offer substantial symptomatic improvement. This communication will focus primarily on nOH, while recognizing that orthostatic symptoms are often multifactorial: i.e., patients with nOH may have their symptoms worsened by medications, hypovolemia, intrinsic cardiovascular disease, and other factors [6, 7]. The literature on nOH is fraught with inconsistencies in the definition and methods of diagnosis, and suffers from a lack of evidence-based guidelines to direct clinicians towards ‘best practice’. As nOH is a subset of orthostatic hypotension (OH), it should be noted that patients with nOH and OH may experience the same symptoms but for different reasons. The following consensus definition of OH was devised by the American Autonomic Society and the American Academy of Neurology, and endorsed by the European Federation of Autonomic Societies and the World Federation of Neurology: OH is “…a sustained reduction of systolic blood pressure of at least 20 mmHg or diastolic blood pressure of 10 mmHg, or both, within 3 min of standing or head-up tilt to at least 60° on a tilt table” [8]. In addition to meeting the definition for OH, patients with nOH have impairment of the autonomic nervous system that is characterized by failure to provide adequate autonomic postural responses, most prominently systemic vasoconstriction and a compensatory increase in heart rate sufficient to maintain blood pressure. This deficit is, in large part, attributed to insufficient norepinephrine release from sympathetic nerves [9]. In addition, many patients with nOH also suffer from supine hypertension, which further confounds therapy because pharmacologic treatments to normalize standing blood pressure may worsen supine hypertension [10]. Differences in study designs and endpoints, as well as a paucity of data, preclude achieving definitive evidence-based treatment regimens through a systematic review of trials [11–22]. To move forward in an effective and safe manner, consensus is required on the basics of screening, diagnosing, and treating patients with nOH. Thus, an expert opinion statement to these basic approaches is needed. To address this issue, the American Autonomic Society and the National Parkinson Foundation jointly held an initial consensus panel meeting to formulate essential recommendations into a working guideline for the screening, diagnosis, and treatment of nOH and associated supine hypertension. Results of the discussions held during the meeting, along with continued deliberations among the panel participants are presented here along with recommendations in each of the topic areas. Whereas most patients with disorders typically associated with nOH are seen by cardiologists or neurologists, particularly movement disorder specialists, the first point of contact and potential for identification of nOH is with the primary care clinicians. Hence, the following consensus commentary is meant to provide guidance for all clinicians who might encounter and/or ultimately manage nOH. SCREENING FOR NOH There is no standardized or recommended screening protocol for patients that present with symptoms of orthostatic hypotension. Presenting symptoms and signs of OH include postural lightheadedness or dizziness, the sensation of blacking out, and falls with or without syncope. Less common symptoms include orthostatic cognitive dysfunction (executive function worsens significantly during the orthostatic challenge in patients with autonomic dysfunction, possibly because of transient frontal lobe hypoperfusion), mental dulling, generalized weakness, neck pain or discomfort in the suboccipital and paracervical region (‘coat hanger’ configuration—a manifestation of hypotension-induced ischemia of the strap muscles of the neck), or platypnea (dyspnea while standing due to OH causing inadequate perfusion of ventilated lung apices or ventilation perfusion mismatch) [23–27]. Thus, screening for nOH starts with questions to identify the symptoms of OH followed by measurement of blood pressures from the supine (or seated) to standing position (recommended specific technique for timing of blood pressure measurements is detailed below) [6]. It may be beneficial if screening questionnaires and blood pressure measurements are conducted by a qualified non-physician (such as a nurse) prior to the patient’s visit with the clinician. Patients in the following five categories need to be routinely screened for OH: - Patients suspected of, or diagnosed with any neurodegenerative disorder associated with autonomic dysfunction, including Parkinson’s Disease (PD), Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), or Dementia with Lewy Bodies (DLB); - Patients who have reported an unexplained fall or have had an episode of syncope; - Patients with peripheral neuropathies known to be associated with autonomic dysfunction (e.g., diabetes, amyloidosis, HIV); - Patients who are elderly (≥70 years of age) [28] and frail or on multiple medications; - Patients with postural (orthostatic) dizziness or non-specific symptoms that only occur when standing. Patients in each of these groups have a higher risk of OH/nOH when compared to the normal population [29]. For these five categories of patients, clinicians should ask about cardinal symptoms of OH, their frequency and severity, how long they can stand, and the effect of symptoms on their activities of daily living. Questions about symptoms should also note the time of day when the symptoms occur, as symptoms of OH/nOH are most likely to occur in the morning and after meals [30–32]. A more complete list of questions to use when screening patients for OH/nOH is presented in Table 1. If a patient gives a positive response to one or more of the questions listed in Table 1, they should be considered as being at risk for OH/nOH and a more

Read the complete text